GRI Bio's Upcoming Presentation at the Annual Investment Conference
GRI Bio, Inc. (NASDAQ: GRI), an innovative biotechnology firm specializing in Natural Killer T (NKT) cell modulators, is gearing up for a significant presentation at the H.C. Wainwright 26th Annual Global Investment Conference. This event is set to occur from September 9 to September 11, 2024, in New York City. Dr. Marc Hertz, the Chief Executive Officer of GRI Bio, will lead the presentation.
What to Expect from the Presentation
At this pivotal event, GRI Bio plans to provide valuable insights into its groundbreaking therapies aimed at treating inflammatory, fibrotic, and autoimmune diseases. Dr. Hertz will discuss the company's recent advancements and engage with attendees about future opportunities. Additionally, the management team will participate in one-on-one meetings with qualified investors who are registered for the conference.
Investors Can View the Webcast
For those unable to attend in person, a video webcast of the presentation will be available for on-demand viewing. The webcast will be accessible starting on September 9, 2024, at 7:00 AM ET, and can be found on the Events page in the Investors section of GRI Bio’s official website. Furthermore, GRI plans to archive the webcast replay for 90 days after the event, allowing all interested investors and stakeholders to catch up on the presentation at their convenience.
About GRI Bio, Inc.
GRI Bio, Inc. is a clinical-stage biopharmaceutical company that is transforming the treatment landscape for inflammatory, fibrotic, and autoimmune diseases. By concentrating on modulating NKT cell function, which plays a crucial role in regulating immune responses, GRI Bio aims to halt disease progression and restore immune balance. Their lead candidate, GRI-0621, effectively inhibits iNKT cell activity and is being developed as a novel oral therapy specifically for idiopathic pulmonary fibrosis, a serious condition with significant unmet medical needs. The company is also advancing a promising pipeline of novel type 2 NKT agonists designed to treat systemic lupus erythematosus, underscoring its commitment to tackling critical health challenges.
Investor Relations Contact
For additional inquiries, investors can reach out to the JTC Team, led by Jenene Thomas. She can be contacted at (833) 475-8247, and emails can be sent to GRI@jtcir.com.
Frequently Asked Questions
1. When will GRI Bio present at the conference?
The presentation is scheduled for September 9-11, 2024, at the H.C. Wainwright Annual Global Investment Conference.
2. Who will be presenting for GRI Bio?
Dr. Marc Hertz, the Chief Executive Officer, will represent GRI Bio during the conference.
3. Is there a way to watch the presentation remotely?
Yes, there will be a video webcast available for on-demand viewing starting September 9, 2024, at 7:00 AM ET.
4. What is GRI Bio's primary focus?
GRI Bio focuses on developing therapies that modulate NKT cells to treat inflammatory, fibrotic, and autoimmune diseases.
5. How can investors contact GRI Bio for more information?
Investors can contact Jenene Thomas at (833) 475-8247 or via email at GRI@jtcir.com.